文献速递胸部肿瘤

可切除IIIA/B期非小细胞肺癌放疗后心脏剂量暴露作为预后标志物:一项随机试验的二次分析

Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究基于ESPATUE III期试验的二次分析,纳入155例可手术IIIA(N2)/选择性IIIB期非小细胞肺癌患者,评估心脏V5(心脏接受≥5 Gy的体积)和平均心脏剂量对生存的预后价值。多变量分析未证实心脏V5是独立预后因素,肿瘤进展是主要死亡原因。

要点

  • 心脏V5未证实为可手术IIIA/B期NSCLC新辅助或根治性放化疗后的独立预后因素。
  • 多变量分析心脏V5对生存的HR为1.005(95%CI 0.995-1.015,P=0.30),无统计学意义。
  • 肿瘤进展和肺炎是主要死亡原因,分别占观察到的死亡的65%和14%。

核心结论

  • 心脏V5未能被验证为新辅助或根治性适形放化疗后生存的独立预后因素,肿瘤进展是主要死亡原因。

研究设计与样本

  • ESPATUE III期随机试验的二次分析,纳入2004年1月至2013年1月招募的155例可手术IIIA(N2)/选择性IIIB期非小细胞肺癌患者,其3D放疗计划可获取心脏V5和平均心脏剂量。
  • 患者接受顺铂/紫杉醇诱导化疗后新辅助放化疗至45 Gy(1.5 Gy每日两次,同步顺铂/长春瑞滨),可手术者随机分配至根治性放化疗组(A组)或手术组(B组),两组放疗总剂量不同。

主要发现

  • 多变量分析调整肿瘤和临床特征后,心脏V5不是生存的独立预后因素(HR 1.005,95%CI 0.995-1.015,P=0.30);不调整下叶肿瘤位置时HR为0.999(95%CI 0.986-1.012,P=0.83)。
  • 心脏V5对无肿瘤进展死亡无影响。
  • 肿瘤进展和肺炎是主要死亡原因,分别占观察到的死亡的65%和14%。

关键数值与推荐

  • 心脏V5定义为心脏接受≥5 Gy的局部体积。
  • 该数据集有80%把握度检测到RTOG 0617中所发现大小的心脏V5预后效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart exposure to ionizing irradiation can cause ischaemic heart disease. The partial heart volume receiving ≥5 Gy (heartV5) was supposed to be an independent prognostic factor for survival after radiochemotherapy for locally advanced non-small-cell lung cancer (NSCLC). But validation of the latter hypothesis is needed under the concurrent risks of lung cancer patients. PATIENTS AND METHODS: The ESPATUE phase III trial recruited patients with potentially operable IIIA(N2)/selected IIIB NSCLC between 01/2004 and 01/2013. Cisplatin/paclitaxel induction chemotherapy was given followed by neoadjuvant radiochemotherapy (RT/CT) to 45 Gy (1.5 Gy bid/concurrent cisplatin/vinorelbine). Operable patients were randomized to definitive RT/CT(arm A) or surgery (arm B) and therefore were treated at two different total dose levels of radiotherapy. HeartV5 and mean heart dose (MHD) were obtained from the 3D radiotherapy plans, the prognostic value was analysed using multivariable proportional hazard analysis. RESULTS: A total of 161 patients were randomized in ESPATUE, heartV5 and MHD were obtained from the 3D radiotherapy plans for 155 of these [male/female:105/50, median age 58 (33-74) years, stage IIIA/IIIB: 54/101]. Power analysis revealed a power of 80% of this dataset to detect a prognostic value of heartV5 of the size found in RTOG 0617. Multivariable analysis did not identify heartV5 as an independent prognostic factor for survival adjusting for tumour and clinical characteristics with [hazard ratio 1.005 (0.995-1.015), P = 0.30] or without lower lobe tumour location [hazard ratio 0.999 (0.986-1.012), P = 0.83]. There was no influence of heartV5 on death without tumour progression. Tumour progression, and pneumonia were the leading causes of death representing 65% and 14% of the observed deaths. CONCLUSIONS: HeartV5 could not be validated as an independent prognostic factor for survival after neoadjuvant or definitive conformal radiochemotherapy. Tumour progression was the predominant cause of death. REGISTER NO: Z5 - 22461/2 - 2002-017 (German Federal Office for Radiation Protection).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Guberina M, Eberhardt W, Stuschke M, et al. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial. Ann Oncol. 2017. PMID: 28453703. doi:10.1093/annonc/mdx069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。